<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460861</url>
  </required_header>
  <id_info>
    <org_study_id>MD-URO-00021</org_study_id>
    <nct_id>NCT02460861</nct_id>
  </id_info>
  <brief_title>Intraoperational Prostate Loge Biopsies (iPROLOGX) After Radical Prostatovesiculectomy</brief_title>
  <acronym>iPROLOGX</acronym>
  <official_title>Intraoperational Prostate Loge Biopsies (iPROLOGX) After Radical Prostatovesiculectomy (RPVE) in Prostate Cancer (PCA) Patients for Molecular Tumor Marker Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Magdeburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Antonius Hospital Gronau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Magdeburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is about the detection of occult tumor cells in surgical margins of radical
      prostatovesiculectomy by analysing the methylation status of Glutathione S-transferase P 1
      (GSTP1). After gland excision specimens are obtained from 9 defined areas of the prostatic
      fossa. The biopsies are divided into two parts. One part used for histopathological analysis
      and the other part for moleculargenetic analysis. Results will be correlated e.g. with tumor
      stage, Gleason Score and prostate specific antigen (PSA).

      The prostate-cancer-negative control group with bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is about the detection of occult tumor cells in surgical margins of radical
      prostatovesiculectomy by analysing the methylation status of Glutathione S-transferase P 1
      (GSTP1). After gland excision specimens are obtained from 9 defined areas of the prostatic
      fossa. The biopsies are divided into two parts. One part used for histopathological analysis
      and the other part for moleculargenetic analysis. Results will be correlated e.g. with tumor
      stage, Gleason Score and prostate specific antigen (PSA).

      The prostate-cancer-negative control group with bladder cancer.

      DNA ISOLATION

      DNA from biopsies stored by -80°C was isolated by using innuPREP DNA mini Kit (Analytik Jena,
      Jena, Germany) following protocol 1 of the manufacturer's instructions. DNA was eluted with
      50 µl elution buffer. Concentration and purity were analysed by using Nanodrop 2000.

      DNA BISULFITE MODIFICATION

      DNA was modified by using EpiTect Bisulfite Kit (QIAGEN, Hilden, Germany) according to
      manufacturer's instructions. Samples were eluted once with 20 µl elution buffer.

      QUANTITATIVE METHYLATION SPECIFIC PCR

      Methylation status of GSTP1 is analysed by quantitative methylation-specific PCR (Q-MSP)
      using StepOnePlus Real-Time PCR System and StepOne Software v2.1 from Applied Biosystems
      (Darmstadt, Germany). Q-MSP was performed in duplicate analysing genes Actin and GSTP1. The
      primers' and testing probes' sequences used to amplify and detect hypermethylated GSTP1 were:
      5'-AgTTgCgCggCgATTTC (forward primer), 5'-gCCCCAATACTAAATCACgACg (reverse primer) and
      5'-CggTCgACgTTCggggTgTAgCg (taqman probe), labelled with fluorescence dye FAM. The primers'
      and testing probes' sequences used to amplify and detect Actin were:
      5'-TggTgATggAggAggTTTAgTAAgT (forward primer), 5'-AACCAATAAAACCTACTCCTCCCTTAA (reverse
      primer),5'-ACCACCACCCAACACACAATAACAAACACA (taqman probe), labelled with fluorescence dye VIC.

      The Q-MSP was carried out at 50°C for 2 min., 95°C for 15 min. followed by 50 cycles of 95°C
      for 1s and 60°C for 1 min. As a positive control bisulfite-converted DNA of DU145 and LNCap
      were used. Blank reactions with destillated water, which replaced DNA, served as negative
      control (NTC).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Methylation status of GSTP1</measure>
    <time_frame>2 years</time_frame>
    <description>Methylation status of GSTP1 is analysed by quantitative methylation-specific PCR (Q-MSP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Histopathology of prostate fossa biopsies</measure>
    <time_frame>2 years</time_frame>
    <description>Histopathology of prostate fossa biopsies (Prostata cancer positive or negative)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">279</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>PCA Magdeburg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prostate cancer conducted for RPVE with curative Intention, biopsies of the prostatic fossa in Magdeburg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-prostate cancer Magdeburg/Gronau</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conducted for CE in Male with bladder cancer or other indication for cystectomy but without prostate cancer in Magdeburg or Gronau, biopsies of the prostatic fossa in Gronau</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCA Gronau</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prostate cancer conducted for ETRARP with curative Intention, biopsies of the prostatic fossa</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsies of the prostatic fossa in Magdeburg</intervention_name>
    <description>intraoperative Open surgical biopsies of the prostatic fossa after prostatevesiculectomy in Magdeburg</description>
    <arm_group_label>PCA Magdeburg</arm_group_label>
    <arm_group_label>Non-prostate cancer Magdeburg/Gronau</arm_group_label>
    <other_name>surgical biopsies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RPVE</intervention_name>
    <description>Open Radical prostatovesiculectomy in Magdeburg</description>
    <arm_group_label>PCA Magdeburg</arm_group_label>
    <other_name>surgical prostatectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ETRARP</intervention_name>
    <description>Robotassisted Radical prostatovesiculectomy in Gronau</description>
    <arm_group_label>PCA Gronau</arm_group_label>
    <other_name>surgical prostatectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CE</intervention_name>
    <description>Open cystectomy in Magdeburg/Gronau</description>
    <arm_group_label>Non-prostate cancer Magdeburg/Gronau</arm_group_label>
    <other_name>surgical cystoprostatectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsies of the prostatic fossa in gronau</intervention_name>
    <description>intraoperative endoscopic robotassisted biopsies of the prostatic fossa after prostatevesiculectomy in Gronau</description>
    <arm_group_label>Non-prostate cancer Magdeburg/Gronau</arm_group_label>
    <arm_group_label>PCA Gronau</arm_group_label>
    <other_name>surgical biopsies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria for patients with prostate adenocarcinoma:

        Inclusion Criteria

          -  sex: male

          -  diagnosis: prostate adenocarcinoma

          -  treatment: radical prostatovesiculectomy

          -  period of treatment: 11/30/2011 - 10/15/2013

        Exclusion Criteria

          -  sex: female

          -  diagnosis: no prostate adenocarcinoma

          -  treatment: no radical prostatovesiculectomy

          -  period of treament: before 11/30/2011 or after 10/15/2013

        Criteria for prostate adenocarcinoma negative control group:

        Inclusion Criteria

          -  sex: male

          -  diagnosis: urothelial carcinoma

          -  treatment: cysto-prostatectomy

          -  period of treament: 12/14/2011 - 02/18/2014

        Exclusion Criteria

          -  sex: female

          -  diagnosis: incidental prostate adenocarcinoma

          -  treatment: no cysto-prostatectomy

          -  period of treatment: before 12/14/2011 or after 02/18/2014
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Schostak, Prof.Dr.med.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Magdeburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Gronau</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Urology, University Clinic Otto von Guericke University Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>May 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>May 29, 2015</last_update_submitted>
  <last_update_submitted_qc>May 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Magdeburg</investigator_affiliation>
    <investigator_full_name>Johann J. Wendler, MD</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Molecular staging</keyword>
  <keyword>GSTP1</keyword>
  <keyword>Surgical margins</keyword>
  <keyword>prostatovesiculectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

